EUVIMEDEUVIMED entdecken
Open Access

Unlocking Therapeutic Potential: Camphorquinone’s Role in Alleviating Non-Alcoholic Fatty Liver Disease via SIRT1/LKB1/AMPK Pathway Activation

Nagarajan Maharajan, Kil Hwan Kim, Karthikeyan A Vijayakumar, Gwang-Won Cho

Tissue Engineering and Regenerative Medicine · 2025

DOI: 10.1007/s13770-024-00684-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Tissue Engineering and Regenerative Medicine, 2025. Verfasst von Nagarajan Maharajan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, Head and Neck Surgery, University of Maryland School of Medicine, Baltimore, MD, 21201, USA. Hauptthemen laut MEDLINE: Sirtuin 1, Non-alcoholic Fatty Liver Disease, AMP-Activated Protein Kinases, Protein Serine-Threonine Kinases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: VHS Medical Center Research Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is a pathological condition that increase the risk of simple steatosis to hepatocellular carcinoma. This study aimed to investigate the biological effects of camphorquinone (CQ) in a high-fat diet (HFD)-fed and low dose streptozotocin (STZ)-induced mouse model, widely used to mimic the concurrent development of NAFLD pathological conditions in vivo, and a free fatty acid-induced hepatic steatosis cell model in vitro. METHODS: CQ (10 or 30 mg/kg/day; i.p.) was injected for three weeks, and fasting blood glucose levels, glucose tolerance, and liver lipid metabolism were assessed. RESULTS: CQ administration alleviated the increase in body and liver weights and improved glucose tolerance in NAFLD mice model. CQ also reduced the gene expression levels of lipid biosynthesis and inflammation markers, while increasing the levels of fatty acid oxidation markers in liver tissues and HepG2 cells. These beneficial effects of CQ were mediated via activation of the sirtuin 1 (SIRT1)/adenosine monophosphate-activated protein kinase (AMPK) signalling pathway in vitro and in vivo. CONCLUSION: Collectively, our data suggest that CQ improves liver lipid metabolism and reduces blood glucose levels via activation of the SIRT1/serine/threonine kinase 11 (STK11/LKB1)/AMPK axis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sirtuin 1Non-alcoholic Fatty Liver DiseaseAMP-Activated Protein KinasesProtein Serine-Threonine KinasesSignal TransductionMice, Inbred C57BLAnimalsHumansMaleMiceHep G2 CellsDiet, High-FatLipid MetabolismLiverAMP-Activated Protein Kinase KinasesDisease Models, AnimalCamphor

Stichwörter der Autor:innen

AMPKCamphorquinoneNon-alcoholic fatty liver diseaseSIRT1

Substanzen

Sirtuin 1AMP-Activated Protein KinasesProtein Serine-Threonine KinasesStk11 protein, mouseSirt1 protein, mouseAMP-Activated Protein Kinase KinasesSTK11 protein, humanCamphor

Autor:innen und Institutionen

  • Department of Otorhinolaryngology, Head and Neck Surgery, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
  • Veterans Health Service Medical Center, Veterans Medical Research Institute, Seoul, 05368, Korea.
  • Department of Biological Science, College of Natural Sciences, Chosun University, 309 Pilmun-Daero, Dong-Gu, Gwangju, 501-759, Korea.
  • The Basic Science Institute of Chosun University, Chosun University, Gwangju, 61452, Korea.
  • Department of Biological Science, College of Natural Sciences, Chosun University, 309 Pilmun-Daero, Dong-Gu, Gwangju, 501-759, Korea. gwcho@chosun.ac.kr.
  • The Basic Science Institute of Chosun University, Chosun University, Gwangju, 61452, Korea. gwcho@chosun.ac.kr.

Förderung

  • VHS Medical Center Research Grant

Zitieren

APA

Maharajan, N., Kim, K. H., Vijayakumar, K. A., & Cho, G. W. (2025). Unlocking Therapeutic Potential: Camphorquinone’s Role in Alleviating Non-Alcoholic Fatty Liver Disease via SIRT1/LKB1/AMPK Pathway Activation. Tissue Engineering and Regenerative Medicine. https://doi.org/10.1007/s13770-024-00684-8

Vancouver

Maharajan N, Kim KH, Vijayakumar KA, Cho GW. Unlocking Therapeutic Potential: Camphorquinone’s Role in Alleviating Non-Alcoholic Fatty Liver Disease via SIRT1/LKB1/AMPK Pathway Activation. Tissue Engineering and Regenerative Medicine. 2025. doi:10.1007/s13770-024-00684-8

BibTeX
@article{Maharajan2025,
  author = {Maharajan, Nagarajan and Kim, Kil Hwan and Vijayakumar, Karthikeyan A and Cho, Gwang-Won},
  title = {Unlocking Therapeutic Potential: Camphorquinone’s Role in Alleviating Non-Alcoholic Fatty Liver Disease via SIRT1/LKB1/AMPK Pathway Activation},
  journal = {Tissue Engineering and Regenerative Medicine},
  year = {2025},
  doi = {10.1007/s13770-024-00684-8}
}
Kostenlos starten →